linjc16/ctgov huggingface dataset:
Use of Sterile HemaClear Tourniquet Below Calf Versus Pneumatic Tourniquet at the Thigh for Ankle and Foot Surgery

Study Overview
=================
Brief Summary
-----------------
This is a Randomized controlled trial evaluating the effects of the use of Sterile HemaClear Tourniquet Below Calf Versus Pneumatic Tourniquet at the Thigh for Ankle and Foot Surgery The trial will randomize 60 patients into an experimental group with HemaClear or Active comparator group with Pneumatic Tourniquet. The outcomes are: effectiveness of the tourniquet, bleeding escapes, infection, deep vein thrombosis, pain at the tourniquet site, neurologic problems related to the tourniquet

Official Title
-----------------
Use of Sterile HemaClear Tourniquet Below Calf Versus Pneumatic Tourniquet at the Thigh for Ankle and Foot Surgery

Conditions
-----------------
Foot Fracture, Ankle Fractures, Ankle Injuries, Foot Injuries and Disorders

Intervention / Treatment
-----------------
* Device: HemaClear
* Device: Pneumatic Tourniquet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ankle and foot surgery Exclusion Criteria: Infection Tumors Open fracture Burns Varicose veins Isquemia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HemaClear<br> | Device: HemaClear<br>* HemaClear Model A<br>* Other names: HemaClear Model A;|
| Active Comparator: Pneumatic Tourniquet<br> | Device: Pneumatic Tourniquet<br>* Pneumatic Tourniquet<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| infection rates | infection rates | after 1 week | 
| infection rates | infection rates | after 3 months | 
| Deep vein thrombosis | Deep vein thrombosis (Clinical assessment and Doppler ultrasound) | after 1 week | 
| Deep vein thrombosis | Deep vein thrombosis (Clinical assessment and Doppler ultrasound) | after 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| local pain | local pain at the tourniquet site (Visual Analogue Scale) | after 1 week | 
| local pain | local pain at the tourniquet site (Visual Analogue Scale) | after 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Foot Fracture, Ankle Fractures, Ankle Injuries, Orthopaedic Devices Associated with Misadventures, Foot Injuries and Disorders
Does Increase in Appetite After Iron Treatment Induced by Ghrelin Hormone

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine whether iron therapy in patients with intravenous iron deficiency anemia causes an increase in appetite. And whether this increase is mediated by the hormone ghrelin.

Detailed Description
-----------------
Prior to Iron treatment Investigator will sample subject blood for: counting blood, iron sector indices, renal function, electrolytes, and measure the level of ghrelin fasting plasma. In addition, the patient will fill a structured questionnaire that examines appetite levels. participants will be asked to answer a structured questionnaire which will include information on demographics, clinical data (fever, allergies, weight, height) and comorbidities. Additional data on laboratory tests, comorbidities, medication and regular blood and urine cultures results will be taken from the medical file. Iron treatment will be given according to local standard procedure . At the end of the treatment ghrelin levels and questionaire will be retaken . iron deficiency anemia is defined: hemoglobin <12 gr / dl in women and Hb <13 gr / dl in men with ferritin <15 ng / ml.

Official Title
-----------------
Does Increase in Appetite After Iron Treatment Induced by Ghrelin Hormone

Conditions
-----------------
Anemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Iron deficiency anemia that wasn't responded to oral treatment or wasn't tolerable due to side effects sign and dated informed consent form. Exclusion Criteria: chronic inflammatory disease. chronic renal failure active cancer. active Infectious disease. non iron deficiency anemia. pregnancy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| intravenous (IV) iron therapy<br>Patients register to intravenous (IV) iron therapy due to iron deficiency anemia that wasn't responded to oral treatment or wasn't tolerable due to side effects. 20 mL of blood will be draw for complete blood count, renal function, electrolytes and ghrelin. In addition, the patient will fill a structured questionnaire that examines the appetite of the patient before and after treatment. At the end of Iron administration Ghrelin will be retested. | |
| healthy volunteer<br>healthy volunteer, will be asked 20 mL of blood will be draw for complete blood count, renal function, electrolytes and ghrelin. In addition, the patient will fill a structured questionnaire that examines his appetite. Ghrelin will be retested after 6 weeks. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ghrelin levels after treatment with Intravenous Iron |  | 12 weeks |
Uterine Closure for Cesarean Section: a Novel Technique

Study Overview
=================
Brief Summary
-----------------
In here we want to describe a new technique to uterin closure at caesarean section which has been performed about 20 years by Bülent Yılmaz. The technique (we suggest the name of the technique as Yılmaz technique) provide less resuturing need when closing the uterus in cesarean section, bringing together better wound edges, providing more effective suture in thin uteruses, stopping active bleeding areas with the same suture, thus enabling to complete the surgery at low cost by using a single suture material in almost all cases. The aim of this study is to describe the technique and compare the blood loss of patients in caserean section between Yılmaz technique and single layer continue locked suturation .

Detailed Description
-----------------
The participants of the study were divided into two groups as uterine closure with Yilmaz technique (study group) and single layer continue locked suturation (control group). Maternal age, gestationale age, fetal weight, preoperative and postoperative hemoglobin levels are recorded. Hemoglobin decrease was calculated by subtracting the postoperative hemoglobin value from the preoperative hemoglobin values of the pregnant women.The postoperative hemoglobine decrease of the groups are compared.

Official Title
-----------------
All Layer Continuous Paralel Uterine Closure for Cesarean Section: a Novel Technique

Conditions
-----------------
Cesarean Section Complications, Cesarean Section; Dehiscence

Intervention / Treatment
-----------------
* Procedure: Yilmaz Suturation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients underwent to ceseren section and singleton alive fetus Exclusion Criteria: The patients with uterine atonia, coagulaopathy, plasenta previa blood transfusion -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Yilmaz Technique<br>the patients underwent ceserean section and uterus closed with Yilmaz Technique | Procedure: Yilmaz Suturation<br>* uterine closure with Yilmaz Technique and single layer continue locked suturation<br>|
| single layer continue locked suturation<br>the patients underwent ceserean section and uterus closed with single layer continue locked suturation | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decrease of hemoglobine levels | Comparision of postoperative decrease of hemoglobine levels between Yilmaz Technique and single layer continue locked suturation | 1 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cesarean section, uterine closure, novel technique
Outpatient Chest Tube Management Following Thoracic Resection Improves Patient Length of Stay and Satisfaction Without Compromising Outcomes

Study Overview
=================
Brief Summary
-----------------
Discharging patients home with air leak and chest tube to portable drainage device after thoracic resection is cost effective and safe without compromising patients outcome or satisfaction. Despite good outcomes this practice is not done universally by thoracic surgeons.

Detailed Description
-----------------
Medical chart database to identify patients ,of one thoracic surgeon over the last seven years, who underwent thoracic resection and were discharged home with an air leak and chest tube to portable drainage device was completed. Once all patients were identified, all possible vulnerable patients were discarded. Written consent for participation was obtained by eligible patients and subjects willing to participate were given further explanation of the study. All willing participants completed an Outpatient Chest Tube Quality of Life Questionnaire. Upon completion of the questionnaire participants involvement in the study was complete. Data was collected and correlations between variables statistically analysed to determine significant factors affecting care.

Official Title
-----------------
Outpatient Chest Tube Management Following Thoracic Resection Improves Patient Length of Stay and Satisfaction Without Compromising Outcomes

Conditions
-----------------
Lung Cancer, Pneumothorax, Subcutaneous Emphysema

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients 18-89, all genders, all patients undergoing thoracic resection, all patients discharged with chest tube Exclusion Criteria: minors, all patients > 90 years old, all mentally challenged, all non-English speaking patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Outpatient chest tubes<br>All patients, mixed gender, race, and age, who underwent thoracic resection by one surgeon over the past seven years and discharged home with air leak present and chest tube to portable drainage device. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Outpatient Chest Tube Management Following Thoracic Resection Improves Patient Length of Stay and Satisfaction Without Compromising Outcomes | Outcome measures for this study were to correlate outpatient chest tube management with patient satisfaction. Also to correlate decreased length of stay without compromising any patient outcomes. | 2 years |
Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics. - 1

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test the utilization of incentive values (considerably lower than those typically used in research clinics) to motivate clients to attend treatment and initiate and sustain abstinence.

Detailed Description
-----------------
The purpose of the proposed research is to implement and systematically evaluate, in community treatment settings, motivational incentive procedures that have been well researched and have proven efficacious in a variety of treatment research clinics. The study will determine if motivational incentives along with standard care therapy is more effective than standard therapy alone for the treatment of patients using cocaine or methamphetamine and entering a substance abuse treatment program.

Official Title
-----------------
Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics

Conditions
-----------------
Substance-Related Disorders

Intervention / Treatment
-----------------
* Behavioral: Behavior Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Recent admission to an opioid substitution (methadone maintenance) CTP. Completed at least 4 weeks of maintenance at time of study entry Evidence of cocaine or methamphetamine use Minimum of one documented positive urine within 2 weeks of study entry. For those exiting a controlled environment, any stimulant use within two weeks of entering the controlled environment Exclusion Criteria: Unable to give informed consent (fails simple consent quiz) Answers yes to question: Are you in recovery from gambling? That is, have you stopped gambling because of previous gambling problems?

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Behavior Therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ASI |  |  | 
| Opioid and cocaine use |  |  | 
| AIDS risk behavior |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
substance use disorders
Autologous Oral Mucosa Transplantation for Limbal Stem Cell Deficiency

Study Overview
=================
Brief Summary
-----------------
PURPOSE: To report clinical and histochemical results of oral mucosa graft transplantation in eyes with limbal stem cell deficiency. DESIGN: Prospective observational study. METHODS: 32 eyes of 27 patients with limbal stem cell deficiency underwent direct oral mucosa graft transplantation with amniotic membrane transplantation with a mean follow-up of 19 months. Clinical course of the disease including emergency surgeries, planned curative procedures, conjunctival inflammation, acute inpatient treatment and best corrected visual acuity were assessed at 3 months postoperatively and at last follow up visit. The unneeded parts of oral mucosa graft were analyzed immunohistochemically with staining for mesenchymal stem cell markers and pericytes (CD 90, CD 146, CD 166, CD 31, CD 68, protein gene product).

Official Title
-----------------
Autologous Oral Mucosa With Amniotic Membrane Transplantation for Limbal Stem Cell Deficiency: Clinical and Immunohistochemical Study

Conditions
-----------------
Limbal Stem-cell Deficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: limbal stem cell deficiency at least in one eye undergoing oral mucosa with amniotic membrane transplantation obtained written informed consent Exclusion Criteria: no written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in number of acute surgeries |  | baseline, 3 months after oral mucosa transplantation; through study completion, an average of 19 months | 
| change in days of acute inpatient treatment |  | baseline, 3 months after oral mucosa transplantation; through study completion, an average of 19 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in number of curative surgical procedures after oral mucosa transplantation |  | baseline, 3 months after oral mucosa transplantation; through study completion, an average of 19 months | 
| change in conjunctival inflammation |  | baseline, 3 months after oral mucosa transplantation; through study completion, an average of 19 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Limbal Stem-cell Deficiency, Oral mucosa transplantation, Amniotic membrane, Mesenchymal stem cells
Prognosis of a First-Ever Stroke in Persons Living With HIV

Study Overview
=================
Brief Summary
-----------------
With aging of the persons living with HIV, cardiovascular diseases now account for substantial mortality and morbidity. Stroke frequency grows exponentially with aging and its incidence doubles every decade over 55 years of age. The prognosis of ischemic stroke depends mainly on the care in Stroke Units in the acute phase of the disease (thrombolysis/thrombectomy). It is important that HIV patients are referred to these units in the first hours of a stroke and not to their infectious disease units which is a loss of chance. It would also be important to know whether HIV patients need specific protocols for stroke emergency management. The study aims to compare the functional prognosis after the first occurrence of an ischemic stroke, in patients admitted to a Stroke Unit, whether they are infected or not infected by HIV.

Conditions
-----------------
Cerebrovascular Accident, Acute, HIV

Intervention / Treatment
-----------------
* Other: stroke center referral


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients unexposed to HIV: HIV-1 seronegative OR patients exposed to HIV: HIV seropositive for over 6 months with or without antiretroviral treatment. Confirmed by Elisa and Western blot tests admitted for ischemic stroke, defined as a sudden cerebrovascular event confirmed by MRI at least 18 years of age paired with patients unexposed to HIV, admitted for ischemic stroke, same gender and age Exclusion Criteria: antecedents of a symptomatic ischemic or hemorrhagic cerebrovascular event no social security benefits; Absence of signed informed consent for the study Patients currently pregnant or breast-feeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HIV patients<br>HIV patients admitted in Stroke units for the first occurence of acute stroke | Other: stroke center referral<br> <br> |
| non HIV patients<br>non HIV patients admitted in Stroke units for the first occurence of acute stroke | Other: stroke center referral<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| degree of disability measured with the modified Rankin Scale |  | 3 months |
Effect of Ankle-foot Orthoses Trim Line Modifications on Ankle and Knee Motion and Force.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to quantify changes in ankle and knee motion and force resulting from five progressive modifications to the anterior-posterior trim lines of thermoformed ankle-foot orthoses (AFO). It is hypothesized that the AFO with the most anterior trim line will prevent the most plantar flexion during loading response (the first 10% of the gait cycle)and prevent the most dorsiflexion at terminal stance (from 30 to 50% of the gait cycle) as compared to the non-device condition. This will be evidenced by the sagittal plane ankle motion and ground reaction force magnitude and location during loading response and terminal stance. Additionally, the angular velocity of knee flexion will increase during these same periods. By contrast, as the trim lines are moved more posterior this will result in lowering the effective stiffness of the device which will result in progressive increases in dorsiflexion and allow increasing amounts of knee flexion during terminal stance.

Official Title
-----------------
Effects of Varying Trim Lines of Solid Ankle-foot Orthoses on Ankle and Knee Kinematics and Kinetics During Stance Phase.

Conditions
-----------------
Lower Extremity Biomechanics

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants must have no known pathology that would affect their ambulatory ability. Age greater than or equal to 18 years, but less than 40 years. Ability to tolerate walking for a minimum of 100 yards over the course of a three and a half hour time period. No current skin breakdown or sores on either lower extremity. Exclusion Criteria: Use of ambulatory aids such as canes or crutches. Any medical or psychological condition that could jeopardize the subject's participation and compliance with the study protocol.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sagittal plane ankle angle. |  | Six months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sagittal plane knee angle. |  | Six months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Kinetics, Ankle, Knee, Orthosis, Kinematics